Nuvation Bio (NUVB) awards stock options and RSUs to company officer

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that officer Makunje Moses received new equity awards. On February 27, 2026, Moses was granted stock options for 224,439 shares at an exercise price of $0.00 per share and 50,761 shares of Class A Common Stock as restricted stock units (RSUs).

The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months, contingent on continued service. The RSUs vest in four equal annual installments on the issuer’s quarterly vesting date following each of the first four anniversaries from February 27, 2026, also conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Makunje Moses

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	224,439	$0.00	--
Grant/Award	Class A Common Stock	50,761	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 224,439 shares (Direct); Class A Common Stock — 68,137 shares (Direct)

Footnotes (1)

1. Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date. Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan. Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Makunje Moses

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/27/2026		A		50,761(1)	A	$0	68,137(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		224,439		(3)	02/26/2036	Class A Common Stock	224,439	$0	224,439	D

Explanation of Responses:

1. Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 25% of the shares subject to the RSUs shall vest on the Issuer's quarterly vesting date following each of the first four anniversaries from 2/27/2026, subject to Reporting Person's continuous service on each such vesting date.

2. Includes 1,001 shares acquired on May 19, 2025 and 1,100 shares acquired November 19, 2025 under the 2021 Employee Stock Purchase Plan.

3. Option vests as to 25% on the one year anniversary of 2/27/26, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

Remarks:

Title: VP, Finance and principal financial and accounting officer.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvation Bio (NUVB) report for Makunje Moses?

Nuvation Bio reported that officer Makunje Moses received equity awards, not an open-market trade. He was granted stock options for 224,439 shares and 50,761 restricted stock units of Class A Common Stock, all awarded at a grant price of $0.00 per share.

How many Nuvation Bio (NUVB) stock options were granted to Makunje Moses?

Makunje Moses was granted stock options covering 224,439 shares of Nuvation Bio Class A Common Stock. These options vest 25% on the one-year anniversary of February 27, 2026, then continue vesting monthly over the next 36 months, subject to his continued service.

What restricted stock units (RSUs) did Makunje Moses receive from Nuvation Bio (NUVB)?

He received 50,761 RSUs, each representing one share of Class A Common Stock upon settlement. The RSUs vest in four equal parts on the issuer’s quarterly vesting dates following each of the first four anniversaries from February 27, 2026, assuming continuous service.

Are the Nuvation Bio (NUVB) equity awards to Makunje Moses immediately vested?

No, the equity awards are subject to time-based vesting. The stock options vest over four years, with 25% after one year and the rest monthly. The 50,761 RSUs vest in four equal annual installments tied to future quarterly vesting dates.

What is the exercise price of the Nuvation Bio (NUVB) stock options granted to Makunje Moses?

The stock options granted to Makunje Moses carry an exercise price of $0.00 per share. Although awarded at no cost, he must satisfy the time-based vesting schedule, including a one-year cliff and subsequent monthly vesting, before exercising fully.

How many Nuvation Bio (NUVB) shares does Makunje Moses own after the RSU grant?

Following the RSU grant, Makunje Moses beneficially owns 68,137 shares of Nuvation Bio Class A Common Stock directly. This figure includes shares previously acquired under the company’s 2021 Employee Stock Purchase Plan, as detailed in the filing’s footnotes.